The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

Parkinson’s Disease (PD) is a common brain disorder that affects movement and is most often linked with aging. It’s the second most common age-related brain disease, affecting millions worldwide.

The current study was based on previous evidence in DLB, Parkinson's, and Alzheimer's disease, Turner said ... The overall ...

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

Can a common parasite help treat Alzheimer’s? Scientists say Toxoplasma gondii may open pathways to brain therapies for ...

Nilotinib (Tasigna) — a drug for myeloid leukemia — improved biomarkers and cognitive outcomes in study participants with dementia with Lewy bodies, a new study finds.

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial ... unlock the vast therapeutic potential of the inflammasome pathway.” ...

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

Researchers discovered alcohol use disorder (AUD) and Alzheimer's disease (AD) exhibit similar patterns of gene dysregulation, hinting that alcohol consumption may hasten Alzheimer’s progression.

Critical Path Institute today announced key leadership appointments: Diane Stephenson, Ph.D., has been promoted to Vice President of Neurology, and Nadine Tatton, Ph.D., has been welcomed as the new ...

The findings align with an earlier study that showed possible disease-modifying effects of nilotinib ... that perhaps we need ...